Free Trial
→ NNVC FDA = New Momentum Wave! (From Equiscreen) (Ad)tc pixel Free FARN Stock Alerts

Faron Pharmaceuticals Oy (FARN) Competitors

Faron Pharmaceuticals Oy logo
GBX 42 +0.50 (+1.20%)
As of 12:23 PM Eastern
Compare

FARN vs. BTG, ARIX, SCLP, CIR, and TILS

Should you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include BTG (BTG), Arix Bioscience (ARIX), Scancell (SCLP), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to BTG?

Faron Pharmaceuticals Oy (LON:FARN) and BTG (LON:BTG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 19.3% of BTG shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 19.8% of BTG shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Faron Pharmaceuticals Oy's return on equity of 45.13% beat BTG's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
BTG N/A N/A N/A

BTG has a consensus target price of GBX 160, indicating a potential upside of 35.59%. Given BTG's stronger consensus rating and higher probable upside, analysts clearly believe BTG is more favorable than Faron Pharmaceuticals Oy.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Faron Pharmaceuticals Oy
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BTG
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

BTG has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
BTG£159.40M1.19N/A£6.0019.67

In the previous week, Faron Pharmaceuticals Oy and Faron Pharmaceuticals Oy both had 3 articles in the media. Faron Pharmaceuticals Oy's average media sentiment score of 0.43 beat BTG's score of 0.19 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Faron Pharmaceuticals Oy
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BTG
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

BTG beats Faron Pharmaceuticals Oy on 9 of the 11 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Arix Bioscience. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arix Bioscience. Faron Pharmaceuticals Oy's average media sentiment score of 0.43 beat Arix Bioscience's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Overall Sentiment
Arix Bioscience Neutral
Faron Pharmaceuticals Oy Neutral

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Arix Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Arix Bioscience105.64% 6.41% 2.18%
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arix Bioscience£14.16M0.00£14.96M£0.11N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 3.9% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arix Bioscience has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.178, indicating that its stock price is 18% more volatile than the broader market.

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Scancell?

Faron Pharmaceuticals Oy (LON:FARN) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 15.5% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Faron Pharmaceuticals Oy had 1 more articles in the media than Scancell. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 2 mentions for Scancell. Faron Pharmaceuticals Oy's average media sentiment score of 0.43 beat Scancell's score of 0.10 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Faron Pharmaceuticals Oy
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Scancell
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Faron Pharmaceuticals Oy has a beta of 1.178, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Scancell has a beta of 0.573, meaning that its stock price is 43% less volatile than the broader market.

Scancell has higher revenue and earnings than Faron Pharmaceuticals Oy. Scancell is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Scancell£4.71M40.75-£6.75M-£0.55N/A

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Faron Pharmaceuticals Oy's return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Scancell -116.98%90.29%-45.28%

Summary

Faron Pharmaceuticals Oy and Scancell tied by winning 6 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Circassia Group (LON:CIR) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Circassia Group. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Circassia Group. Faron Pharmaceuticals Oy's average media sentiment score of 0.43 beat Circassia Group's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Overall Sentiment
Circassia Group Neutral
Faron Pharmaceuticals Oy Neutral

Circassia Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Circassia Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

1.6% of Faron Pharmaceuticals Oy shares are held by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Faron Pharmaceuticals Oy beats Circassia Group on 5 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Faron Pharmaceuticals Oy (LON:FARN) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 0 mentions for Tiziana Life Sciences. Faron Pharmaceuticals Oy's average media sentiment score of 0.43 beat Tiziana Life Sciences' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
Tiziana Life Sciences Neutral

Tiziana Life Sciences has lower revenue, but higher earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Faron Pharmaceuticals Oy's return on equity of 45.13% beat Tiziana Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 45.13% -70.00%
Tiziana Life Sciences N/A N/A N/A

1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 3.9% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Faron Pharmaceuticals Oy beats Tiziana Life Sciences on 7 of the 9 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FARN vs. The Competition

Export
MetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON Exchange
Market Cap£83.80M£457.64M£6.28B£2.76B
Dividend YieldN/A3.86%2.78%6.14%
P/E Ratio-1.904.1420.49365.60
Price / SalesN/A7,693.05544.5288,654.25
Price / Cash20.0013.1327.8127.89
Price / Book0.0279.789.587.52
Net Income-£60.23M-£96.07M£3.55B£5.89B
7 Day Performance-2.89%0.32%-0.82%7.44%
1 Month Performance-1.18%3.15%5.46%2.90%
1 Year Performance-80.73%73.68%37.70%89.21%

Faron Pharmaceuticals Oy Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FARN
Faron Pharmaceuticals Oy
N/AGBX 42
+1.2%		N/A-81.6%£83.80MN/AN/A34
BTG
BTG
3.8778 of 5 stars		GBX 118.50
-0.8%		GBX 160
+35.0%		N/A£190.85M£159.40M19.754,690
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
SCLP
Scancell
N/AGBX 15.10
+7.9%		N/A+88.6%£156.71M£4.71MN/A51
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 5/12/2026 by MarketBeat.com Staff.
From Our Partners
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targe...
Equiscreen | Sponsoredtc pixel
Rise of the… petroyuan?
On February 28th, Iran installed a yuan-denominated toll at the Strait of Hormuz - the chokepoint for one in e...
Golden Portfolio | Sponsoredtc pixel
BSEM: From OTC to Nasdaq Contender!
BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...
Huge Alerts | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
If You Have $50k+ on Coinbase, This Will Ruin Your Day
In 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...
Decentralized Masters | Sponsoredtc pixel
SpaceX Launches Strange 'Dark Energy' Across America
SpaceX is deploying a newly permitted energy technology - one that analyst Joel Litman calls 'Dark Energy' - t...
Altimetry | Sponsoredtc pixel